Systemic Therapy of Metastatic Breast Cancer: The Truth Beyond the Clinical Trials

Uwe Gueth, Dorothy Jane Huang, Andreas Schoetzau, Wolfgang Holzgreve, Edward Wight
2009 Oncology  
1990 to 1997, to 21 months in the period from 1998 to 2000 (p = 0.062). Conclusion: The number of patients who died from metastatic breast cancer without receiving any antineoplastic therapy was surprisingly high. The use of newer agents and regimens in the treatment of metastatic breast cancer was associated with an improved survival over time. Chemotherapy is a feasible option also among older patients. Abstract Objective: To depict a clear and coherent picture of the overall course of
more » ... ive treatment in an unselected study cohort over the course of time. Methods: We compared therapy type and course of 242 women whose distant metastatic disease was diagnosed from 1990 to 2006 and who ultimately died of the disease. We divided the patients into two subgroups depending on the year of diagnosis of metastases (group A: 1998-2006 vs. group B: 1990-1997). Results: In both subgroups, there were no significant differences in the general type of treatment and the number of administered therapy lines (no systemic therapy: 12.9 vs.13.7%, p = 0.848; endocrine therapy only: 20.4 vs. 25.2%, p = 0.430; chemotherapy only: 18.4 vs.16.9%, p = 0.735; sequential combination regimen including endocrine therapy/chemotherapy/ trastuzumab: 46.9 vs. 44.2%, p = 0.694; median: 2 lines). In the cases where chemotherapy was administered, there were no differences between the number of lines among older and younger patients (median: two lines; 6 70 years vs. ! 70 years: p = 0.269). The median metastatic disease-specific survival increased from 16 months in the period from
doi:10.1159/000205387 pmid:19246949 fatcat:xlno2tfd4ngj5e7utewmhxnko4